Pharmaceutical composition, particularly for use in the treatment or prevention of cancer
The combination of actinomycin D and nutlin-3a with FAS ligand sensitizes cancer cells to apoptosis, addressing the challenge of limited cancer cell sensitivity and hepatotoxicity by achieving effective cancer cell death with reduced FAS ligand doses, dependent on functional p53 for its efficacy.
Patent Information
- Application Number
- PCT/PL2024/050036
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-26
- Filing Date
- 2024-05-27
- Publication Date
- 2024-12-05
AI Technical Summary
Current cancer treatments face challenges in effectively sensitizing cancer cells to apoptosis induced by FAS receptor agonists, leading to potential hepatotoxicity due to high doses required and limited sensitivity, especially in cells with intact p53 function.
A pharmaceutical composition combining actinomycin D, nutlin-3a, and FAS ligand significantly sensitizes cancer cells to apoptosis, demonstrating synergistic activity that preferentially targets cancer cells over normal cells, thereby reducing the required dose of FAS ligand and minimizing side effects.
The combination of actinomycin D and nutlin-3a enhances the sensitivity of cancer cells to FAS ligand-induced apoptosis, achieving significant cell death with lower FAS ligand concentrations, specifically targeting cancer cells while sparing normal cells and relying on functional p53 for efficacy.
Smart Images

Figure 000014 
Figure 000015 
Figure 000016
Abstract
Description
[0001] Pharmaceutical composition, particularly for use in the treatment or prevention of cancer
[0002] The subject of the invention is the pharmaceutical composition, particularly for use in the treatment of cancer and its use in the therapy and prevention of the neoplastic disease.
[0003] The chemotherapy of cancer involves the introduction into the cancer cells of the substances, which damage the structures or the critical functions of the cells. One of the functions inhibited by chemotherapeutics is the replication and repair of the genetic material - DNA. The damage of DNA initiates a signaling cascade leading to the cell suicide - apoptosis. The apoptosis is determined by the activation of the proteins known as caspases, which are divided into two groups - initiator caspases and executioner caspases. The initiator caspases are in hierarchy above the executioner caspases, which participate in modification of proteins directly involved in the induction of cell death. Apoptosis is initiated by two different systems. One of them is started in cell organelles known as mitochondria, the second one starts from so called death receptors localized on the cell surface. The binding of a death receptor by its cognate ligand initiates the signaling cascade, which ends in the activation of executioner caspases and cell death. In some cell types, a death receptor, through the initiator caspase 8, directly activates the executioner caspases, whereas in other cell types, the death receptors activate also the mitochondrial pathway, what is associated with the activation of caspase 9. The kay role in the activation of caspases is played by p53 tumor suppressor protein because as a regulator of the gene activity, it is responsible for the upregulation of proteins participating in activation of both pathways of apoptosis - mitochondrial and death receptor-mediated. Because the p53 protein plays very important role in the induction of apoptosis and in cell cycle arrest, its gene (TP53) is frequently inactivated due to mutations in many cancers. However, in some cancer cases the TP53 gene is intact and for this reason some chemotherapeutic agents kill cancer cells by activating p53 protein.
[0004] Actinomycin D (CAS No. 50-76-0) is a substance derived from bacteria acting as an antibiotic with properties of an anticancer agent approved as a drug by FDA (Federal Drug Administration) in 1964. Known by its trade name Dactinomycin, it is used in the treatment of some childhood cancers or soft tissue sarcomas. Actinomycin D is a DNA-binding molecule, blocking, among other things, the synthesis of ribosomal RNA. By a mechanism, which is poorly understood, actinomycin D activates p53 protein with all its consequences.
[0005] Nutlin-3a (CAS No. 675576-98-4) is a molecule invented by Hoffman-La Roche ompany. It was designed to bind to MDM2 protein and specifically block its interaction with p53. Since MDM2 is a negative regulator of p53, the application of nutlin-3a activates p53. Considering that the mechanism of p53 activation by actinomycin D and by nutlin-3a differ, a hypothesis was generated that the common action of both molecules (A+N combination) can further enhance the activity of p53. The experiments yielded results consistent with this hypothesis (Zajkowicz et aL, 2015). The primary experimental model was A549 cell line derived from lung cancer but similar effect of A+N combination on p53 activity was observed in cell lines derived from other cancers. However, in spite of strong activation of p53 and cell cycle arrest, the apoptosis measures by flow cytometry and by estimation of caspase-3 activity was observed only in small fraction of cells exposed to A+N (Zajkowicz et aL, 2015, Lasut-Szyszka et aL, 2021 ). The analysis by RNA sequencing of the activity of all known genes in cells exposed to A+N resulted in detection of upregulation of many pro-apoptotic genes including the ones, which promote receptor-mediated cell death.
[0006] Initially the activation of death receptors was considered to inhibit the growth and progression of cancers. However, in the light of recently published data it appears that the impact of the agonists of death receptors on the growth of cancer cells is not obvious. It could be expected that the application of factors, which promote the production of death receptors, e.g., FAS receptor (alias CD95) will sensitize cancer cells to apoptosis. However, a research paper published in the prestigious scientific journal Nature (Chen et aL, 2010) demonstrated that cancer cells regardless their sensitivity to apoptosis dependent on CD95, for the optimal growth conditions require the constitutive activity of CD95 receptor (FAS) stimulated by its ligand (FASLG) supplied by the cancer cells themselves. The authors suggested that unexpected promotion of cancer cell growth by FAS ligand and receptor may be employed in an innovative cancer treatment involving not stimulation but inhibition of FAS receptor. The latest data concerning this topic has been presented in the reviews (Peter et aL, 2014, Risso et aL, 2022).
[0007] The second problem with use of FAS receptor agonists as factors, which kill cancer cells involves the capacity of the agonists to kill liver cells. The FAS receptor can be stimulated either by its natural ligand or be an engineered antibody, which specifically binds to the receptor and stimulates its activity as the natural ligand does. Some research groups successfully generated such antibody in order to use them in cancer therapy aimed at the induction of apoptosis in tumor cells. However, a major roadblock appeared in therapeutic application of this antibody. Its application in mice resulted in death of animals within several hours due to fulminant hepatitis (Ogasawa et aL, 1993). Thus, considering the resistance of cancer cells to apoptosis induced by FAS ligand, the researchers had to use high dose of the antibody, what in turs resulted in hepatotoxicity.
[0008] Considering the problems mentioned above, there is the necessity of rising the sensitivity of cancer cells to the agonists of FAS receptor, what would enable application of the lower dose of the agonists decreasing the risk of serious side effects particularly to the liver. The above-mentioned goal has been unexpectedly reached in this invention. The subject of the invention is pharmaceutical composition and its use as defined in detail in the attached patent claims.
[0009] The essence of the invention relates to use in the cancer treatment and / or cancer prevention of the composition consisting of actinomycin D, nutlin-3a and the FAS ligand.
[0010] During the in vitro experiments it was unexpectedly found that the treatment of cancer cells with the combination of actinomycin D and nutlin-3a significantly sensitized the cells to the pro-apoptotic activity of the FAS ligand (FASLG). The sensitizing effect results from the synergistic activity of actinomycin D and nutlin-3a and is directed primarily toward cancer cells. It was found that the sensitizing effect takes place in larger degree in cancer cells (lung cancer cell line A549, osteosarcoma cell line U-2 OS and gastric carcinoma cell line AGS) than in normal human fibroblasts.
[0011] Considering the molecular mechanism of nutlin-3a activity, which binds MDM2 in a molecular pocket, which in physiological conditions is bound by p53, it can be expected that other molecules, e.g., idasanutlin and RG7112, which can also bind to this pocket and show better pharmacokinetic and pharmacodynamics activities compared with nutlin-3a (Kocik et al., 2019), will also cooperate with actinomycin D in sensitizing cells to FASLG. This hypothesis was positively tested by our experiments.
[0012] Figures
[0013] Figure 1 shows that the exposure of cells first to A+N combination and subsequently to FASLG induces strong activation of the initiator caspases (CASP-8, CASP-9) and the executioner caspase (CASP-3). A549 cells were treated with actinomycin D (ActD, 5nM) and nutlin-3a (Nut3a, 5 pM) for 48 h and subsequently in the fresh medium the cells were exposed to FASLG at indicated concentrations for 2.5 h. The Western blotting method was used to determine the amount of proteins listed on the right-hand side. Full-length (inactive) forms of caspases are marked by arrows. The asterisks mark the cleaved forms of caspases, which are either fully active (CASP-3, CASP-8) or on the way to full activation (CASP-9). The amount of HSC70 is used as a control for equal loading of protein lysates on the gel. The left-hand side shows the molecular weight markers (kDa).
[0014] Figure 2 shows that actinomycin D (ActD) and nutlin-3a (Nutl) acting solo sensitize to apoptosis far less than when combined (A+N). A549 cells were exposed for 46 h to the aforementioned substances (in concentrations given above) and following the change of medium the cells were treated with FASLG in given concentrations for 2 h. The protein lysates were used for the immunodetection of unmodified caspase-9 (CASP9, upper band) or caspase-9 at the initial stage of activation (marked by asterisks, the employed antibody does not detect the fully active form). The lack of full-length caspase-9 in cells exposed to FASLG at 100 ng / ml concentration indicates that apoptosis was induced in most cells. Figure 3 shows that the cell viability test (MTS assay) detects synergistic activity of actinomycin D (ActD) and nutlin-3a (Nut3a) in sensitizing the cells to the cytotoxic activity of FASLG. A549 cells were exposed to the aforementioned substances acting solo and in combnation (ActD+Nut3a) for 45 h and subsequently the cells in the fresh medium were treated with FASLG for 5 h in concentrations shown on the graph (5, 10, 25 ng / ml). In separate culture dish, the cells were exposed only to FASLG (the group marked as Control). After 24 h the MTS assay was performed. The cell viability was presented in %, setting as 100% the viability of cells exposed neither to the drugs nor to FASLG (the first left-hand column). The graph shows means and standard deviations from four independent repeats. The statistical significance of the differences was calculated by two way ANOVA, Tukey's multiple comparisons test (*P < 0.05, **P < 0.01 , ***P < 0.001 ).
[0015] Figure 4 shows that the application of A+N combination significantly lowers the number of cells surviving the treatment with A+N. Equal number of A549 cells were seeded onto the wells of 12-well culture plates. The next day the cells were exposed to the indicated substances acting solo or in combination (A+N) at concentrations given earlier. After 45 h, the culture medium was changed and FASLG was added to the indicated wells for 5 h. Subsequently, the medium was changed again and the surviving cells were allowed to grow for 96 h. The fixed cells were visualized by staining with crystal violet.
[0016] Figure 5 demonstrates that that the combination A+N sensitizes U-2 OS cells (derived from osteosarcoma) to the activity of FASLG. The experiment was performed according to the protocol presented for Figure 4.
[0017] Figure 6 demonstrates that the cytotoxic activity of A+N+FASLG combination is weak in normal human fibroblasts (GM07492). The cells were treated according to the protocol described for Figure 4.
[0018] Figure 7 demonstrates that combination A+N+FASLG is more toxic for cancer cells (A549) than for normal cells (fibroblasts GM07492). The time course of the experiment was as described for Figure 4. Both cell types were pre-exposed only to A+N, with or without subsequent FASLG treatment. The concentrations of the ligand are presented on the figure.
[0019] Figure 8 demonstrates that the cells with damaged gene for p53 protein (TP53) totally loos the sensitivity to the cytotoxic activity of A+N+FASLG combination. The cells with TP53 gene damaged by CRISPR / Cas9 technology (A549-CRISPR-p53), their controls (A549- CRISPR-control) or the unmodified parental cell line (A549) were exposed to A+N (second and third column) or were left untreated (the first and fourth column) for 45 h. Subsequently, the cells in third and fourth column were exposed to FASLG at 100 ng / ml concentration for 5 h. Next, the surviving cells were allowed to grow for 110 h. After this time the cells were fixed and stained with crystal violet. Figure 9 demonstrates that the cytometric analysis detects strong activation of apoptosis in cells exposed to actinomycin D, nutlin-3a and FASLG and confirms the key role of p53 protein in the activation of apoptosis resulted from exposure to the aforementioned substances. A549 cells were treated with A+N combination and subsequently with FASLG as shown on the figure. The control cells were not exposed, the other groups were exposed only to A+N or FASLG. Two cell types were used: p53-deficient cells (CRISPR-p53) or their controls (CRISPR-CON). After the treatment the cells were stained with Annexin V (to visualize apoptotic cells) and with 7-AAD (to visualize the necrotic or late apoptotic cells). The staining procedure also enabled the visualization of viable cells. The percentage of the aforementioned cell populations is given on the vertical bars. The frequency of indicated cell populations of p53-proficient and p53-deficient A549 cells was measured in four biological replicates. The statistical significance of the differences was calculated using Brown-Forsythe ANOVA test and Welch Anova test, Dunnett's T3 multiple comparisons test, **P < 0.01 , ***P < 0.001 .
[0020] Figure 10 demonstrates that pre-treatment with actinomycin D and nutlin-3a sensitizes another cancer cell line (AGS) to the proapoptotic activity of FASLG. This cell line has wildtype p53 and is derived from stomach cancer. This cell line was exposed as shown (ActD, Nut3a, A+N for 45h, and subsequently to FASLG for 2.5h) and the expression of indicated caspases was detected by Western blotting. The asterisks mark the activated forms of caspase-8 (CASP8) and caspase-9 in cells exposed to 25 ng / ml FASLG. It is clearly seen that also in this cell line actinomycin D and nutlin-3a synergize in cell sensitization to the proapoptotic activity of FASLG. At 100 ng / ml concentration of FASLG virtually all molecules of caspase-8 were activated (no full-length form is visible, see the arrow) and the amount of active caspase-3 is very high, what indicates that in most cells apoptosis was activated.
[0021] Figure 11 demonstrates that other antagonists of p53-MDM2 interactions idasanutlin (IDA) and RG7112 (RG) also synergize with actinomycin D in sensitization of cancer cells to the pro-apoptotic activity of FASLG. A. A549 cells were pre-exposed to actinomycin D, RG7112 (RG) or to both substances (ActD+RG) and subsequently they were treated for 2.5h with 50 ng / ml FASLG. Western blot shows the expression of the indicated proteins. B. A similar experiment as in A was performed with Idasanutlin (IDA) in place of RG7112 as an antagonist of MDM2. The arrows indicate full-length (inactive) caspase-8 and caspase-9. They are no longer visible only in cells pre-exposed to actinomycin D and the antagonist of MDM2 and subsequently treated with FASLG. Thus, only the cells preexposed to actinomycin D and the antagonist of MDM2 are very sensitive to apoptosis induced by FASLG.
[0022] The detailed description of some embodiments
[0023] During preliminary experiments, which led to the achievement of the invention it was tested whether prior treatment with A+N would sensitize the cells to the activity of the FAS ligand. In physiological conditions the ligand of FAS receptor - FASLG is localized on the surface of the immune cells. Such immune cell forms a connection with cancer cells in a such a way that FAS ligands on the former make a contacts with FAS receptors on the latter what initiates apoptosis on the cancer cell.
[0024] In the presented experiments a commercially available, modified version of FAS ligand was used with deleted transmembrane domain and soluble in water (Human Fas ligand / TNFRSF6 Protein, His Tag, active trimer (MALS verified), Cat. No. FAL-H5241 , AcroBiosystems, Seq. no. is.: 1 ). It is genetically modified version of the FAS ligand with two domains removed - the transmembrane domain and a cytoplasmic domain localized at the amino terminus. This modified molecule consists of amino-acids Pro-134-Leu 281 (Accession AAH17502.1 ) and it lacks the first 133 amino-acids of the original protein. To the proline at the amino-terminus (Pro-134) a polyhistidine tag is attached. The protein was synthesized in human HEK293 cells and forms a trimer (three identical monomers are joined together). The observed molecular weight of the monomer (25-33 kDa) is larger than expected (18.8 kDa) due to the glycosylation it underegoes during the synthesis in HEK293 cells.
[0025] Figure 1 shows the results of the first experiment. The microscopic observation revealed that the application of the FAS ligand to A549 cells, which were earlier exposed to A+N for 48 h, resulted in death of most cells within only 2.5 h. The viable and dead cells were collected and the immunodetection revealed the activation of caspases. Activation of these proteins involves their proteolytic cleavage. The inactive caspase retains its original length whereas the active caspase is shorter. This illustration shows the amount of the different forms of caspase-8 (the caspase activated by death receptor), of caspase-9 (the caspase activated by mitochondrial apoptotic pathway) and of caspase-3 (the executioner caspase).
[0026] In cells exposed only to A+N (second lane) the p53 protein was distinctly activated (what is manifested as its accumulation), however neither of the caspases was activated. The application of FASLG alone (in two concentrations) lead to small activation of caspase-8, however it did not lead to activation of downstream caspases-9 and 3. Only when FASLG was applied to the cells exposed earlier to A+N, all of the examined caspases were strongly activated. Such cells lack the full-length, unmodified caspases (marked by arrows on the illustration) what indicates that the apoptosis was initiated virtually in all cells. Thus, definitely the exposure of cells to A+N strongly and decisively sensitizes A549 cells to FASLG-induced apoptosis.
[0027] To convincingly show that it is the combination that sensitizes cells to apoptosis and not one of the compounds acting alone, in the next experiment the cells were treated separately with actinomycin D, nutlin-3a or with their combination. To each of these treatments the FAS ligand was added at two concentrations 25 or 100 ng / ml. We used the activation status of caspase-9 as a marker of apoptosis. The results are presented on Figure 2. When FASLG was used at 25 ng / ml concentration the activation of caspase-9 appeared only in cells treated earlier with A+N. Neither actinomycin-D nor nutlin-3a caused the sensitization to apoptosis triggered by FASLG at 25 ng / ml concentration. The effect of the substances acting solo is visible only when FASLG is applied at 100 ng / ml concentration, however also in this case the drugs synergize in the sensitizing effect. The amount of active caspase-9 in cells pre-exposed to A+N combination is larger when compared with separate treatment with the drugs.
[0028] Therefore, the robust sensitizing effect was observed only when the two substances were combined (A+N). The quantify this effect, the classic cell viability test (MTS assay) measuring the general metabolic activity of cells was performed. It is widely-used test to measure the cytotoxic activities of substances and treatments. In this experiment the cells were exposed to the drugs separately or in combination for 48 h and subsequently FASLG was applied at three concentrations (5, 10, 25 ng / ml) for 5 h. The other group of cells was exposed only to FASLG in the aforementioned concentrations. The results are presented on Figure 3.
[0029] The results are consistent with the ones presented on Figure 2. The application of FASLG at 5 ng / ml concentration does not reduce the viability of cells pre-exposed to actinomycin D or nutlin-3a or of the mock-treated control cells, however, pre-exposure of cells to A+N reduces the metabolic activity of cells from 41 % to 25% of the control. In case of higher concentrations of FASLG (10 and 25 ng / ml), the difference between the mono-treatment and combined treatment is even larger. Considering the drop of metabolic activity of cells without prior treatment and exposed to FASLG at 25 ng / ml concentration (100%->87,67% of control) and the drop of metabolic activity of cells pre-exposed to A+N and subsequently treated with FASLG at 25 ng / ml concentration (41 %->0.33% of control), it can be estimated that the treatment with A+N increased the sensitivity of cells to FASLG at this concentration by a factor of 100.
[0030] In the next experiment a different method was used to visualize the impact of the treatment on the survival of cells (Fig. 4). The cells were seeded in equal number on the wells of 12-well plates. The next day the 45-hour treatment was started (the drugs acting solo or combined). Subsequently, after the change of culture medium, FASLG at two concentrations (25, 100 ng / ml) was added for 5 h. Next, the fresh medium was added and the cells were allowed to grow for 3 days. After this, the cells were fixed, stained with crystal violet in order to visualize the cell density on each well. The results of the experiment are presented on Figure 4.
[0031] The results of test with this form of visualization (Fig. 4) is consistent with the results of the detection of caspase activity (Fig. 2) or the measurement of metabolic activity (Fig. 3). Treatment with the substances without application of FASLG slightly reduced the cell density (the first row). The exposure to FASLG at 25 ng / ml concentration did not cause discernible drop in cell density when the cells were preatreated with the drugs acting solo. However, when FASLG was applied to cells pre-exposed to the drug combination (A+N), most cells died (middle row). Actinomycin D and nutlin-3a acting solo slightly sensitized cells to FASLG at 100 ng / ml concentration, however the effect was weaker when compared with the drug combination (bottom row).
[0032] The same experiment was performed on other cancer cell line (U-2 OS, derived from osteosarcoma) and the synergistic cooperation between actinomycin D and nutlin-3a resulting in increased FASLG-induced apoptosis was also observed (Fig. 5).
[0033] In the next step the influence of the drug combination on normal cells was tested (Fig. 6). The fibroblasts (GM07492) derived from Coriell Cell Repositories were selected. The experiment was carried out as in the case of cancer cells, however, the synergistic activity of actinomycin D and nutlin-3a on the sensitization for FASLG-induced apoptosis (25 ng / ml) was not observed (Fig. 6). In order to compare the sensitivity of cancer cells and normal cells more precisely we performed the experiment simultaneously on the same plate (Fig. 7). Cancer cells and normal cells were exposed to A+N and subsequently to FASLG in the following concentration: 3.3, 10, 30 and 90 ng / ml. At the lowest concentration FASLG did not impact on the density of either normal or cancer cells. At 10 ng / ml and 30 ng / ml concentrations FASLG distinctly reduced the density of cancer cells but did not significantly reduce the density of normal cells. At the highest concentration (90 ng / ml). FASLG killed most of both cancer and normal cells (Fig 7).
[0034] In the next experiment, the role of p53 in the induction of cell death by A+N and FASLG was assessed. By the methods of genetic engineering the cells with mutant p53 were created (A549-CRISPR-p53). The control cells for modification (A549-CRISPR-control) and the parental, unmodified cells (A549) were also tested. The results are presented on Fig. 8. The p53-deficient cells are not killed by the applied drug combination (pre-treatment with A+N with subsequent exposure to FASLG for 5 h). Thus, the applied drug combination can kill only the cells with functional p53 protein.
[0035] The impact of the A+N+FASLG combination on apoptosis and the regulation of this process by p53 was also studied using flow cytometry. The simultaneous cell staining with Annexin-V and 7-AAD allows for discerning three cell populations: viable, late apoptotic / necrotic and early apoptotic. The results presented on Fig. 9 indicate that only the treatment with A+N+FASLG significantly increase the percentage of cells in early apoptosis and the percentage of dead cells. Their total number exceeds 50% only two hours since the start of treatment with FASLG. This increase of apoptotic or dead cells is barely visible in p53- deficient cells. Therefore, the death of cells exposed to A+N+FASLG is indeed apoptosis, and two independent tests confirm that this process critically depends on the presence of functional p53 protein.
[0036] In the next experiment another cell line was tested for the sensitivity to FASLG-induced apoptosis following treatment with actinomycin D and nutlin-3a. The AGS cell line, with wildtype p53 and derived from stomach cancer was treated in standard fashion with A+N+FASLG as indicated on Fig. 10. The synergy between actinomycin D and nutlin-3a was best visible when treated cells were exposed to 25 ng FASLG. For this concentration of the ligand actinomycin D or nutlin-3a acting solo induce only small activation of caspase-8 and caspase- 9, whereas when the two compounds are combined the activation of both caspases by the ligand is very strong. The treatment with A+N and the addition of FASLG at 100 ng / ml concertation result of strong activation of apoptosis in most cells. Thus, AGS cell line is another example of cancer cell line able to undergo extensive apoptosis following the treatment with A+N+FASLG.
[0037] Finally, as suggested earlier, we tested if other antagonists of p53-MDM2 interaction - idasanutlin and RG7112 are able to substitute for nutlin-3a in cooperation with actinomycin D in sensitization of cells to proapoptotic activity of FASLG. The data presented on Fig. 11 indicate that it is the case, because both compounds, when combined with actinomycin D induce strong activation of caspase-8 and caspase-9 when the cells are treated with FASLG at 50 ng / ml concentration.
[0038] Conclusions
[0039] 1. The experiments presented above, carried out using various methods (assessment of caspase activation status, MTS assay, visualization of cell density using crystal violet staining, flow cytometry), clearly demonstrated that the treatment of cancer cells with the combination of actinomycin D and nutlin-3a conspicuously sensitized cancer cells to proapoptotic activity of the ligand of FAS receptor (FASLG). The sensitizing effect of both substances is synergistic.
[0040] 2. The pre-treatment with A+N enables the application of lower concentration of FASLG to achieve the proapoptotic activity of this ligand. During the in vivo use, the pre-treatment with A+N and lower concentration of FASLG may prevent the potential hepatotoxicity of the ligand. In other words A+N significantly lowers the threshold of sensitivity of cancer cells to apoptosis induced by FASLG.
[0041] 3. The application of A+N with subsequent treatment with FASLG at 25 ng / ml concentration for 5 h kills more than 99% of cells, what precludes the appearance of plausible growthpromoting activity of FASLG.
[0042] 4. The sensitizing effect of A+N towards the apoptosis induced by FASLG is larger in cancer cells than in normal cells.
[0043] 5. The p53-deficiency of cancer cells totally prevents the sensitizing effect of actinomycin D and nutlin-3a towards apoptosis triggered by FASLG.
[0044] 6. The sensitizing effect of actinomycin D and nutlin-3a can be detected in three cell lines with wild-type p53 of different origin: A549 (lung cancer), U-2 OS (osteosarcoma), AGS (stomach cancer). 7. Other antagonists of p53-MDM2 interactions - idasanutlin and RG7112 also synergize with actinomycin D in sensitization of cancer cells to the pro-apoptotic activity of FASLG.
[0045] References
[0046] Kocik J, Machula M, Wisniewska A, Surmiak E, Holak TA, Skalniak L. Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists. Cancers (Basel). 2019 Jul 19;11 (7):1014. doi: 10.3390 / cancers11071014. PMID: 31331108; PMCID: PMC6678622.
[0047] Krzesniak M, Zajkowicz A, Gdowicz-Klosok A, Glowala-Kosiriska M, Lasut-Szyszka B, Rusin
[0048] M. Synergistic activation of p53 by actinomycin D and nutlin-3a is associated with the upregulation of crucial regulators and effectors of innate immunity. Cell Signal. 2020 May;69: 109552. doi: 10.1016 / j.cellsig.2020.109552. Epub 2020 Feb 4. PMID: 32032660; PMCID: PMC7126238.
[0049] Lasut-Szyszka B, Malachowska B, Gdowicz-Klosok A, Krzesniak M, Glowala-Kosiriska M, Zajkowicz A, Rusin M. Transcriptome Analysis of Cells Exposed to Actinomycin D and Nutlin- 3a Reveals New Candidate p53-Target Genes and Indicates That CHIR-98014 Is an Important Inhibitor of p53 Activity. Int J Mol Sci. 2021 Oct 14;22(20): 11072. doi: 10.3390 / ijms222011072. PMID: 34681730; PMCID: PMC8538697.
[0050] Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh
[0051] N, Suda T, Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature. 1993 Aug 26;364(6440):806-9. doi: 10.1038 / 364806a0. Erratum in: Nature 1993 Oct 7;365(6446):568. PMID: 7689176.
[0052] Peter ME. DICE: A novel tumor surveillance mechanism-a new therapy for cancer? Cell Cycle. 2014;13(9):1373-8. doi: 10.4161 / cc.28673. Epub 2014 Apr 1. PMID: 24690893; PMCID: PMC4050134.
[0053] Risso V, Lafont E, Le Gallo M. Therapeutic approaches targeting CD95L / CD95 signaling in cancer and autoimmune diseases. Cell Death Dis. 2022 Mar 17;13(3):248. doi: 10.1038 / s41419-022-04688-x. PMID: 35301281 ; PMCID: PMC8931059.
[0054] Zajkowicz A, Gdowicz-Klosok A, Krzesniak M, Sciegliriska D, Rusin M. Actinomycin D and nutlin-3a synergistically promote phosphorylation of p53 on serine 46 in cancer cell lines of different origin. Cell Signal. 2015 Sep;27(9):1677-87. doi: 10.1016 / j. cellsig.2015.05.005. Epub 2015 May 16. PMID: 25989210. Sequence listing
[0055] Sekw. Id nr 1:
[0056] 1 mqqpfnypyp qiywvdssas spwappgtvl pcptsvprrp gqrrpppppp ppplpppppp
[0057] 61 pplpplplpp Ikkrgnhstg Icllvmffmv Ivalvglglg mfqlfhlqke laelrestsq
[0058] 121 mhtasslekq ighpspppek kelrkvahlt gksnsrsmpl ewedtygivl Isgvkykkgg
[0059] 181 Ivinetglyf vyskvyfrgq scnnlplshk vymrnskypq dlvmmegkmm sycttgqmwa
[0060] 241 rssylgavfn Itsadhlyvn vselslvnfe esqtffglyk 1
Claims
Claims1. Pharmaceutical composition, especially for the treatment of cancer, characterized in that it contains actinomycin D, nutulin-3a or a derivative thereof and a FAS receptor ligand.
2. The composition according to claim 1 , wherein the FAS receptor ligand comprises the amino acid sequence shown as SEQ. id. 1.
3. The composition according to claim 1. 1 , characterized in that the nutulin-3a derivative is idasanutlin or RG7112.
4. The pharmaceutical composition according to claim 1-3 for use in the treatment or prevention of cancer, containing actinomycin D, nutulin-3a and FAS receptor ligand.
5. The composition for use according to claim 4, characterized in that said active ingredients are used in the same dosage unit or in different dosage units.
